{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-059824","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2026-05-13T12:09:13+00:00","discovered_at":"2026-05-13T12:10:00.353567+00:00","generated_at":"2026-05-13T12:11:22.504689+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Century Therapeutics reports Q1 net loss of $21.6M; cash runway into Q1 2029; CNTY-813 IND on track for 4Q 2026","bullets":["Net loss of $21.6M for Q1 2026 vs net income of $76.6M in Q1 2025; R&D $17.1M, G&A $6.6M.","Cash, cash equivalents and marketable securities $217.0M as of March 31, 2026; runway into Q1 2029.","CNTY-813 (type 1 diabetes iPSC islet) IND submission on track for 4Q 2026; initial clinical data expected 2H 2027; ADA presentation June 8, 2026.","CNTY-308 (CD19 CAR-iT) to enter clinic in 2026 pending regulatory clearance; targeting B-cell mediated diseases.","Completed $135M oversubscribed private placement in January 2026; net cash used in ops $25.3M (down from $34.6M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-059824","json":"https://secwatch.observer/filing/0001104659-26-059824.json","markdown":"https://secwatch.observer/filing/0001104659-26-059824.md","text":"https://secwatch.observer/filing/0001104659-26-059824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926059824/0001104659-26-059824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926059824/tm2614312d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T12:11:22.504689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f565ba41c0e55bc8cf165f7f5f6baeefdbc98754","claim":"Century Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net (loss) was $21.6 million for the quarter ended March 31, 2026, compared to net income of $76.6 million for the same.","evidence_excerpt":"Century Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926059824/0001104659-26-059824-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"Net (loss) was $21.6 million for the quarter ended March 31, 2026, compared to net income of $76.6 million for the same"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}